SMTI (Sanara MedTech) EBIT: $5.3 Mil (TTM As of Mar. 2026)


SMTI Sanara MedTech Inc SMTI
72 GF Score
Price $23.19
GF Value $45.52
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is Sanara MedTech EBIT?

Sanara MedTech SMTI +1.38% 72 EBIT is $5.3 Mil as of Mar. 2026. GuruFocus rates SMTI with a GF Score™ of 72/100 and a GF Value™ of $45.52 (Possible Value Trap). The stock has 6 warning signs investors should review.

Sanara MedTech's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was $2.2 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was $5.3 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Sanara MedTech's annualized ROC % for the quarter that ended in Mar. 2026 was 20.14%. Sanara MedTech's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 189.87%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Sanara MedTech's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 2.17%.

Sanara MedTech  (NAS:SMTI) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Sanara MedTech's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=10.588 * ( 1 - 0% )/( (53.006 + 52.146)/ 2 )
=10.588/52.576
=20.14 %

where

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=72.944 - 5.023 - ( 16.579 - max(0, 18.627 - 33.542+16.579))
=53.006

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=69.277 - 3.537 - ( 13.594 - max(0, 13.701 - 31.198+13.594))
=52.146

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Sanara MedTech's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=8.788/( ( (2.533 + max(-1.311, 0)) + (2.453 + max(4.271, 0)) )/ 2 )
=8.788/( ( 2.533 + 6.724 )/ 2 )
=8.788/4.6285
=189.87 %

where Working Capital is:

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(11.998 + 3.949 + 1.016) - (5.023 + 0 + 13.251)
=-1.311

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(13.617 + 3.121 + 0.866) - (3.537 + 0 + 9.796)
=4.271

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Sanara MedTech's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=5.349/246.634
=2.17 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sanara MedTech EBIT Related Terms

Sanara MedTech EBIT Historical Data

* Premium members only.

The historical data trend for Sanara MedTech's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sanara MedTech EBIT Chart

Sanara MedTech Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -7.99 -13.94 -3.96 1.19 6.37

Sanara MedTech Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.70 -0.23 2.65 0.73 2.20

SMTI vs PDEX, UTMD, EMBC: EBIT Comparison

For the Medical Instruments & Supplies subindustry, Sanara MedTech's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sanara MedTech EV-to-EBIT vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Sanara MedTech's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Sanara MedTech's EV-to-EBIT falls into.


SMTI
72GF Score
Sanara MedTech Inc SMTI
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sanara MedTech EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $5.3 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of $5.3 Mil mean?
Sanara MedTech (SMTI) has a EBIT of $5.3 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Sanara MedTech.
Is Sanara MedTech's EBIT too high?
Sanara MedTech's current EBIT is $5.3 Mil. Overall, Sanara MedTech has a GF Score™ of 72/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Sanara MedTech's EBIT compare to PDEX and UTMD?
Sanara MedTech's EBIT of $5.3 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Medical Devices & Instruments company?
A good EBIT depends on the Medical Devices & Instruments industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Sanara MedTech. Sanara MedTech's current EBIT is $5.3 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sanara MedTech stock overvalued right now?
Based on GuruFocus' analysis, Sanara MedTech (SMTI) is currently considered Possible Value Trap. The stock's GF Value™ is $45.52, compared to a current price of $23.19 — trading 49.1% below its estimated fair value. The current EBIT is $5.3 Mil. Sanara MedTech's overall GF Score™ is 72/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Sanara MedTech (SMTI), the current EBIT is $5.3 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sanara MedTech (SMTI) Overvalued in 2026?

Based on GuruFocus' analysis, Sanara MedTech stock appears to be undervalued. The current stock price of $23.19 is trading 49.1% below its estimated GF Value™ of $45.52. GuruFocus considers Sanara MedTech to be Possible Value Trap.

Key valuation signals for SMTI:

  • EBIT: $5.3 Mil
  • GF Value™: $45.52 vs. price of $23.19 (49.1% below fair value)
  • GF Score™: 72/100 with 6 warning signs

No single metric tells the full story. See the SMTI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sanara MedTech Business Description

Address 1200 Summit Avenue, Suite 414, Fort Worth, TX, USA, 76102
Sanara MedTech Inc is a medical technology company focused on developing and commercializing technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical market. It markets and sells soft tissue repair and bone fusion products for use in operating rooms and sterile environments. Its soft tissue repair products include CellerateRX Surgical Powder, a hydrolyzed collagen used in management of surgical wounds, and BIASURGE Surgical Solution, a sterile no-rinse solution for wound irrigation, while its bone fusion products include BiFORM Bioactive Moldable Matrix, an osteoconductive implant that supports bone growth, and ALLOCYTE Plus Viable Bone Matrix, a human allograft cellular bone matrix containing bone-derived progenitor cells and conformable bone fibers.
72GF Score

Get the complete analysis for SMTI

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$23.19
Price
$45.52
GF Value